Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality by Rojas, Laura J. et al.
Clinical Infectious Diseases
Colistin resistance in CRKp • CID 2017:64 (15 March) • 711
Clinical Infectious Diseases®  2017;64(6):711–8
Colistin Resistance in Carbapenem-Resistant Klebsiella 
pneumoniae: Laboratory Detection and Impact on 
Mortality
Laura J. Rojas,1,2,3 Madiha Salim,4 Eric Cober,5 Sandra S. Richter,6 Federico Perez,3,7 Robert A. Salata,7 Robert C. Kalayjian,8  
Richard R. Watkins,9,10 Steve Marshall,3 Susan D. Rudin,1,3 T. Nicholas Domitrovic,1,3 Andrea M. Hujer,1,3 Kristine M. Hujer,1,3 Yohei Doi,11  
Keith S. Kaye,4 Scott Evans,12 Vance G. Fowler Jr,13,14 Robert A. Bonomo,1,2,3,7,15,16 and David van Duin17; for the Antibacterial Resistance Leadership Group
1Department of Medicine, and 2Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, and 3Research Service, Louis Stokes Cleveland 
Department of Veterans Affairs Medical Center, Cleveland, Ohio; 4Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Michigan; 5Department of Infectious Diseases, 
and 6Department of Laboratory Medicine, Cleveland Clinic, 7Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, 
and 8Department of Medicine, MetroHealth Medical Center, Cleveland, Ohio; 9Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, and 10Division of Infectious 
Diseases, Cleveland Clinic Akron General, Akron, Ohio; 11Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pennsylvania; 12Department of Biostatistics and the Center 
for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts; 13Division of Infectious Diseases, and 14Duke Clinical Research Institute, Duke University, Durham, 
North Carolina; 15Department of Molecular Biology and Microbiology, and 16Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio; and 17Division of 
Infectious Diseases, University of North Carolina, Chapel Hill
Background. Polymyxins including colistin are an important “last-line” treatment for infections caused by carbapenem-resist-
ant Klebsiella pneumoniae (CRKp). Increasing use of colistin has led to resistance to this cationic antimicrobial peptide.
Methods. A cohort nested within the Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRACKLE) 
was constructed of patients with infection, or colonization with CRKp isolates tested for colistin susceptibility during the study 
period of December, 2011 to October, 2014. Reference colistin resistance determination as performed by broth macrodilution was 
compared to results from clinical microbiology laboratories (Etest) and to polymyxin resistance testing. Each patient was included 
once, at the time of their first colistin-tested CRKp positive culture. Time to 30-day in-hospital all-cause mortality was evaluated by 
Kaplan-Meier curves and Cox proportional hazard modeling.
Results. In 246 patients with CRKp, 13% possessed ColR CRKp. ColR was underestimated by Etest (very major error rate = 35%, 
major error rate = 0.4%). A variety of rep-PCR strain types were encountered in both the ColS and the ColR groups. Carbapenem 
resistance was mediated primarily by blaKPC-2 (46%) and blaKPC-3 (50%). ColR was associated with increased hazard for in-hospital 
mortality (aHR 3.48; 95% confidence interval, 1.73-6.57; P < .001). The plasmid-associated ColR genes, mcr-1 and mcr-2 were not 
detected in any of the ColR CRKp.
Conclusions. In this cohort, 13% of patients with CRKp presented with ColR CRKp. The apparent polyclonal nature of the iso-
lates suggests de novo emergence of ColR in this cohort as the primary factor driving ColR. Importantly, mortality was increased in 
patients with ColR isolates.
Keywords. colistin; carbapenem-resistant Enterobacteriaceae; Klebsiella pneumoniae; mortality; ST258.
 
Carbapenem-resistant Klebsiella pneumoniae (CRKp) infec-
tions remain a significant challenge associated with mor-
bidity and mortality worldwide [1, 2]. Few antimicrobials 
retain activity against CRKp [3]. These include aminogly-
cosides, tigecycline, and the recently approved ceftazidime/
avibactam. In addition, polymyxins including colistin are 
an important treatment option [3]. After being mostly 
abandoned in the 1970s, these cationic antimicrobial pep-
tides have reemerged as a “last-line” therapeutic option for 
several multidrug-resistant organisms [4, 5]. In severe CRKp 
infections, colistin is often used in combination with other 
antibiotics including tigecycline, meropenem, gentamicin, 
or fosfomycin [5].
With the rise in consumption of colistin, cases of colis-
tin-resistant Klebsiella pneumoniae carbapenemase (KPC)–
producing strains are reported globally [6]. This emergence 
of colistin-resistant (ColR) in CRKp creates a therapeutic 
challenge that threatens to return clinicians and patients 
to a “pre-antibiotic era.” Here, data from the multicenter 
Consortium on Resistance against Carbapenems in Klebsiella 
pneumoniae (CRACKLE) were analyzed to determine risk fac-
tors for ColR and to compare outcomes of patients with ColR 
CRKp vs colistin-susceptible (ColS) CRKp.
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METHODS
Patients
CRACKLE is a prospective, multicenter, observational study of 
hospitalized patients with CRKp in the Great Lakes region of the 
United States [2, 7–9]. In this nested cohort within CRACKLE, 
patients were included once at the time of their first culture pos-
itive for a CRKp isolate for which in vitro colistin susceptibility 
testing was performed as a part of clinical care at each study 
site from 2011 December to 2014 October. All health systems 
involved in this study had approval from their respective insti-
tutional review board.
Microbiology
CRKp were defined as K.  pneumoniae isolates with nonsus-
ceptibility to any of the following carbapenems: meropenem, 
imipenem, or ertapenem, as outlined by the Clinical and 
Laboratory Standards Institute (CLSI) [10]. Bacterial identi-
fication and routine antimicrobial susceptibility testing were 
performed with MicroScan (Siemens Healthcare Diagnostics) 
or Vitek2 (bioMérieux), supplemented by GN4F Sensititre tray 
(Thermo Fisher) or Etest (bioMérieux), as indicated. Colistin 
minimum inhibitory concentration (MIC) determination was 
performed in clinical microbiology laboratories using Etest and 
was reported as “no interpretation” due to a lack of CLSI and 
Food and Drug Administration (FDA) breakpoints.
Colistin (sulfate salt; Sigma-Aldrich) and polymyxin B 
(Sigma-Aldrich) MIC determination in the central research 
laboratory was performed in duplicate using a broth mac-
rodilution method in glass sterile tubes using Escherichia coli 
ATCC25922 as quality control, according to CLSI guidelines 
[11]. If the 2 MIC values were >1 dilution apart, further repeats 
were performed to determine the final MIC. The final colistin 
MIC thus determined was used to designate ColR vs ColS iso-
lates. In vitro polymyxin resistance was defined per European 
Committee on Antimicrobial Susceptibility Testing guidelines 
as MIC of >2 mg/L [12]. Very major and major error rates were 
defined as described elsewhere [13]. Briefly, very major errors 
were those in which the clinical laboratory result was suscep-
tible and the reference method result was resistant, and major 
errors were defined as those in which the clinical laboratory 
result was resistant and the reference method result was suscep-
tible. Very major and major error rates were calculated using 
the 31 ColR CRKp isolates and the 215 ColS CRKp isolates as 
the denominator, respectively.
Detection of carbapenemase genes and repetitive extragenic 
palindromic (rep)-polymerase chain reaction (PCR) strain typ-
ing was performed as previously described [2]. Briefly, PCR 
amplification of blaKPC, blaNDM, blaVIM, blaIMP, and blaOXA-48 genes 
was conducted using validated primers and methods; amplicons 
were sequenced at a commercial sequencing facility (MCLAB, 
San Francisco, California) and analyzed [14, 15]. rep-PCR was 
performed using the DiversiLab Strain typing system (Bacterial 
BarCodes, bioMérieux, Athens, Georgia). Isolates with ≥95% 
similarity were considered to be of the same rep-PCR type 
[16]. In addition, all ColR CRKp were tested for the presence 
of mcr-1 and mcr-2 through PCR using the following primers: 
mcr-1_F 5’- ATGATGCAGCATACTTCTGTGTGG -3’, mcr-1_R 
5’- GTGCGGTCTTTGACTTTGTCC-3’ (amplifying the com-
plete mcr-1 ORF according to GenBank sequence KU341381.1), 
mcr-2_IF 5’ – TGTTGCTTGTGCCGATTGGA -3’, and mcr-2_
IR 5’ - AGATGGTATTGTTGGTTGCTG -3’ [17].
Clinical Data
Clinical data were entered into a centralized database using the 
electronic medical record (EMR). The index hospitalization 
was recorded as the first hospital stay within the study period 
during which the CRKp was obtained and tested for colistin 
susceptibility. CRKp infections were defined by the standard-
ized criteria described previously [2]. Hospital acquisition was 
defined as timing of the first positive culture more than 2 days 
into the admission. Critical illness was determined as a Pitt bac-
teremia score ≥4 points on the day of the index culture [18]. 
The Charlson comorbidity index was calculated, as described 
elsewhere [19].
Statistics
Differences between groups were analyzed using Wilcoxon 
rank sum for continuous variables. Fisher exact and Pearson 
testing were used for categorical variables where appropriate. 
Kaplan-Meier curves were constructed to compare time to 
30-day in-hospital mortality between groups. Adjusted hazard 
ratios (aHRs) were calculated using Cox proportional hazards 
modeling on time to 30-day in-hospital mortality. In the Cox 
model, all variables were considered that were associated at the 
P < .1 level with the outcome, followed by backward selection. 
P values ≤  .05 were considered statistically significant. JMP 




A total of 522 unique patients were included in the CRACKLE 
study during the study period. Of these 522 patients, 246 (47%) 
had at least 1 isolate that was shipped to the central research 
laboratory that had been tested for colistin susceptibility as part 
of routine clinical care. These 246 patients were included in the 
study. Colistin resistance per research laboratory determination 
(“ColR”) was detected in the CRKp isolates for 31 (13%) patients 
compared to 21 (9%) per clinical laboratory testing. Of note, 
additional colistin MIC testing beyond duplicates was required 
in 25 (10%) isolates; the clinical laboratory reported all of these 
isolates as susceptible. In addition, 25 (10%) of 240 tested iso-
lates were in vitro resistant to polymyxin B as determined by the 
central research laboratory. In the remaining 6 (2%) isolates, a 
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definitive polymyxin B MIC could not be determined in spite of 
repetitive testing, due to the observance of “skipped wells” and 
trailing endpoints.
The distributions of colistin MIC as determined by the cen-
tral research laboratory compared to the clinical microbiology 
laboratories and compared to polymyxin B MIC are shown in 
Figure 1. Testing in the research laboratory resulted in a differ-
ent interpretation in 12/246 (5%) isolates (Figure 1). The very 
major error rate was 35% (11/31), and the major error rate was 
0.4% (1/215).
Clinical Characteristics
Characteristics of patients with ColR vs ColS CRKp were 
similar (Table 1). Overall, 111 (45%) patients met criteria for 
CRKp infection. The anatomic sources of CRKp were urine 
(59%), blood (18%), respiratory system (11%), wound (5%), 
and others (7%). Remarkably, time from admission to first 
positive culture was shorter in patients in the ColR vs ColS 
group; at a median of 0  days (interquartile range [IQR], 
0–3 days) in the ColR group vs 1 day (IQR, 0–9 days) in the 
ColS group (P = .01). The total length of stay (LOS) was also 
shorter for patients with ColR isolates; a median of 8  days 
(IQR, 5–12 days) compared to 13 days (IQR, 7–26 days) in the 
ColS group (P = .01). When only patients who survived their 
hospital stay were analyzed, this difference in LOS was simi-
lar, albeit no longer significant (median 8 vs 12 days; P = .08). 
Finally, a marginal association was observed with prehospi-
talization origin; patients with ColR CRKp were more likely 
to be admitted from home or a long-term acute care facility 
(LTAC), whereas patients with ColS CRKp were more likely 
to be admitted from a skilled nursing facility (SNF) or to be 
transferred from another hospital (P = .05). No specific SNF 
or LTAC appeared to be associated with ColR; 12 patients with 
ColR isolates were admitted from 4 LTACs and 5 SNFs.
Previous Antibiotic Exposure
Antibiotic exposures in the 14 days preceding the first positive 
culture were analyzed (Table  2). In 82 (33%) patients, antibi-
otic use was not documented. In the remaining 164 (67%), 
vancomycin was the single most common drug exposure and 
was given to 80 (33%) patients. Twenty-seven (11%) patients 
received more than 3 classes of antibiotics in the 14-day period 
before the positive culture. Exposure to fluoroquinolones was 
less common in the ColR group compared to the ColS group. 
Otherwise, antibiotic exposures in this time period were not 
different between patients with or without ColR CRKp.
Documented previous colistin use in the 14 days leading up 
to the day of first positive culture was uncommon in the cohort 
as a whole, and patients in the ColR group did not receive 
colistin during this limited time period. Colistin exposure data 
beyond the 14-day period were available for 27 patients with 
ColR isolates, based on EMR of the healthcare system of the 
index hospitalization. In total, 6/27 (22%) patients were found 
to have previous colistin exposure at any time prior to first pos-
itive culture with a ColR CRKp.
Microbiology
The susceptibilities for antibiotics other than colistin were 
determined as clinically indicated by clinical microbiology lab-
oratories (Figure 2). ColR CRKp were significantly less likely to 
be amikacin susceptible; 8/15 (53%) of tested ColR CRKp were 
amikacin susceptible compared to 104/126 (83%) of tested ColS 
CRKp (P =  .02). In contrast, ColR CRKp were more likely to 
be gentamicin susceptible; 21/31 (68%) of tested ColR CRKp 
were gentamicin susceptible compared to 97/212 (46%) of 
tested ColS CRKp (P =  .03). Furthermore, ColR isolates were 
also more likely to be tigecycline nonsusceptible; 13/21 (62%) 
of tested ColR CRKp were tigecycline susceptible compared to 
138/168 (82%) of tested ColS CRKp (P = .04).
Figure 1. The numbers of isolates that correspond to each minimum inhibitory concentration (MIC) value for the MIC as reported by the clinical microbiology laboratories 
(“clinical colistin MIC”) and the centralized research laboratory (“research colistin MIC”), as well as the polymyxin B MIC are shown.
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Overall, a nonclonal distribution was observed. rep-PCR 
suggested that most strains belonged to clades ST258A (n = 76, 
31%) and ST258B (n = 102, 41%). The remaining 68 (28%) iso-
lates belonged to 28 other rep-PCR types. Likewise in the ColR 
group, a nonclonal pattern was observed (Figure 3). rep-PCR 
types corresponding to clades ST258A and ST258B together 
accounted for 77% of ColR isolates.
The presence of carbapenemase genes was confirmed in 
238 (97%) isolates. The carbapenemase genes blaKPC-2 and 
blaKPC-3 were the most common and were found in 113 (46%) 
and 124 (50%) of CRKp isolates, respectively. The distribu-
tion of carbapenemase genes did not differ between ColR and 
ColS CRKp. Of note, blaNDM-1 was found in only 1 isolate. This 
ColS isolate was extensively described previously using whole 
genome sequencing [2]. In the remaining 8 (3%) isolates, car-
bapenemase genes were not detected. The plasmid-mediated 
colistin resistance genes, mcr-1 and mcr-2, were not detected 











 None 82 (33) 10 (32) 72 (33)
 1 51 (21) 9 (29) 42 (20)
 2 51 (21) 5 (16) 46 (21)
 3 35 (14) 5 (16) 30 (14)
 >3 27 (11) 2 (6) 25 (12)
Tigecycline 7 (3) 2 (6) 5 (2) .22
Carbapenem 36 (15) 4 (13) 32 (15) 1.0
Fluoroquinolone 44 (18) 1 (3) 43 (20) .02
Colistin 2 (1) 0 2 (1) 1.0
Vancomycin 80 (33) 8 (26) 72 (33) .54
β-lactam/β-lact-
amase inhibitor
52 (21) 7 (23) 45 (21) .82
Cephalosporin 25 (10) 5 (16) 20 (9) .22
Aminoglycoside 14 (6) 2 (6) 12 (6) .69
Daptomycin 10 (4) 2 (6) 8 (4) .37
Metronidazole 19 (8) 4 (13) 15 (7) .27
Other 90 (37) 11 (35) 79 (37) 1.0
Shown is the documented exposure to antibiotics in 14 days prior to first positive culture. 
All data expressed as n (%).
Figure 2. The percentages of susceptible and intermediate isolates for each drug 
are shown separately for colistin-resistant (ColR) and colistin-susceptible (ColS) car-
bapenem-resistant Klebsiella pneumoniae (CRKp). Underneath each bar is the number 
of CRKp tested for each drug in the ColR and ColS groups. The black and white bars 
represent the percentage of susceptible/tested CRKp isolates in the ColR and ColS 
groups, respectively. The dark-gray and light-gray bars on top of the black and white 
bars represent the percentage of intermediate/tested CRKp isolates in the ColR and 







N 246 31 215
Age in years, median 
(IQR)
67 (54–77) 62 (53–73) 67 (54–78) .43
Female 139 (57) 20 (65) 119 (55) .44
Race/Ethnicity .22
 White 135 (55) 13 (42) 122 (57)
 Black 95 (39) 16 (52) 79 (37)
 Hispanic 7 (3) 0 7 (3)
 Other 9 (4) 2 (6) 7 (3)
Charlson comorbidity 
index, median (IQR)
3 (2–5) 3 (2–4) 3 (2–5) .78
Diabetes mellitus 118 (48) 15 (48) 103 (48) 1.0
Renal failureb 75 (30) 7 (23) 68 (32) .40
Heart disease 121 (49) 14 (45) 107 (50) .70
Chronic obstructive 
pulmonary disease
62 (25) 8 (26) 54 (25) 1.0
Malignancy 41 (17) 8 (26) 33 (15) .19
Infection 111 (45) 13 (42) 98 (46) .85
Source .22
 Urine 144 (59) 16 (52) 128 (60)
 Blood 45 (18) 5 (16) 40 (19)
 Respiratory system 28 (11) 4 (13) 24 (11)
 Wound 13 (5) 1 (3) 12 (6)
 Other 16 (7) 5 (16) 11 (5)
Days to first positive 
culture, median (IQR)
1 (0–7) 0 (0–3) 1 (0–9) .01
Hospital acquisition 115 (47) 10 (32) 105 (49) .12
Origin .05
 Home 90 (37) 14 (45) 76 (35)
 Skilled nursing facility 76 (31) 6 (19) 70 (33)
 Hospital transfer 59 (24) 5 (16) 54 (25)
 Long-term acute care 21 (9) 6 (19) 15 (7)
Critical illnessc 86 (35) 7 (23) 79 (37) .16
Length of stay in days, 
median (IQR)
12 (6–24) 8 (5–12) 13 (7–26) .01
All data expressed as n (%), unless otherwise indicated. 
Abbreviation: IQR, interquartile range. 
aUnivariable relationship between variable of interest and colistin resistance.
bRenal failure defined as creatinine >2 mg/dL on admission.
cCritical illness defined as Pitt bacteremia score ≥4 at the time of index culture.
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Treatment and Mortality
In the first 7  days after the first positive culture, 143 (58%) 
patients received directed treatment. Treatment regimens used 
in these 143 patients are summarized in Table 3. Treatment with 
colistin was uncommon; colistin, either alone or in combination 
with other antibiotics, was given to 31 (22%) of treated patients. 
Colistin treatment was given to 30 of 127 (24%) treated patients 
in the ColS group compared to 1/16 (6%) treated patients 
in the ColR group. Other treatment regimens were similar 
between the 2 groups. The most commonly used antibiotics 
were aminoglycosides and tigecycline. Aminoglycosides were 
given to 72 (50%) of treated patients; 36 (25%) patients received 
only aminoglycosides in the first 7 days. Similarly, 63 (44%) of 
treated patients received tigecycline, of whom 21 (15%) received 
tigecycline monotherapy in the first 7 days.
We evaluated time to all-cause in-hospital mortality, cen-
sored at 30 days (Figure 4). In univariable Kaplan-Meier sur-
vival curves, patients with ColR CRKp were at increased hazard 
of 30-day mortality (P < .0001). After adjustment, the aHR of 
ColR vs ColS was 3.48 (95% confidence interval [CI] 1.73–6.57; 
P  <  .001). Other variables that impacted survival included 
age, pre-hospitalization origin, and anatomical source of the 
Figure 3. Repetitive extragenic palindromic–polymerase chain reaction (rep-PCR) dendrogram of colistin-resistant carbapenem-resistant Klebsiella pneumoniae isolates. 
A ≥95% similarity cutoff (gray line) was used to consider isolates of the same rep-PCR type. Colored boxes next to each strain represent the various hospitals from which 
isolates were recovered. Abbreviation: KPC, klebsiella pneumoniae carbapenemase.
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positive CRKp culture (Table 4). Treatment variables and infec-
tion vs colonization status were not associated with mortality, 
and inclusion of these into the model did not significantly alter 
the association between colistin and mortality. Of note, when 
the colistin resistance as determined by the clinical microbiol-
ogy laboratory was entered into this model instead of ColR as 
determined by the research laboratory, this was still associated 
with increased mortality but to a lesser extent (aHR, 2.78; 95% 
CI, 1.22–5.71; P = .02; data not shown).
DISCUSSION
In this nested cohort of patients from CRACKLE—a prospec-
tive, ongoing, multicenter evaluation of hospitalized patients 
with carbapenem-resistant Enterobacteriaceae (CRE)—a 
ColR rate of 13% was observed in CRKp isolates. This rate was 
underestimated by testing as performed by clinical microbiol-
ogy laboratories. In addition, even testing in optimal research 
conditions resulted in the need for repeat colistin MIC testing 
in 10% of isolates. Furthermore, polymyxin B MIC testing was 
also fraught with difficulties; a definitive polymyxin B MIC 
could not be determined in 6 isolates, even with repetitive test-
ing. The difficulty in determining colistin MIC has been pre-
viously reported by Hindler et al [20]. Broth macrodilution, as 
used here, was found to be the most reliable [20]. The American 
Society for Microbiology recently released a white paper on 
the issue of colistin testing, recommending that “laboratories 
that choose to test for colistin susceptibility should validate 
a broth microdilution method and report MIC values only” 
[21]. Clearly, the absence of FDA breakpoints and the resulting 
impossibility of an FDA-approved test for colistin susceptibility 
remains a major issue.
The association between ColR and mortality was also seen in 
an Italian case-control study on CRKp bloodstream infections 
[22]. In that study 30-day all-cause mortality rates were 51% in 
the ColR group (n = 142) vs 39% in the ColS group (n = 284; 
P  =  .02). The increased mortality may be directly related to 
decreased colistin susceptibility of the organism. Alternatively, 
the observed mortality differences may be secondary to either 
variance in baseline characteristics of patients with ColR vs 
ColS CRKp or to an alteration in the virulence of the pathogen 
[23]. Regardless of causality, it is clear that patients with ColR 
CRKp are at increased risk of hospital mortality.
We observed that—similar to patients with tigecycline-re-
sistant CRKp—isolation of ColR CRKp tended to occur ear-
lier during hospitalization compared to ColS CRKp [7]. Our 
findings suggest that the introduction of ColR isolates may be 
present on admission to acute care hospitals. In the majority 
of patients, colistin exposure prior to the positive culture was 
not documented. This may be explained in a number of ways. 





n 143 16 127
Any colistin in first 7 days 31 (22) 1 (6) 30 (24)
One antibiotic in first 
7 daysa
90 (63) 10 (63) 80 (63)
 Aminoglycoside 36 (25) 5 (31) 31 (24)
 Colistin 10 (7) 1 (6) 9 (7)
 Tigecycline 21 (15) 3 (19) 18 (14)
 Trimethoprim/ 
sulfamethoxazole
13 (9) 0 13 (10)
 fosfomycin 10 (7) 1 (6) 9 (7)
>1 antibiotic in first 7 days 53 (37) 6 (38) 47 (37)
 2 antibiotics 38 (27) 5 (31) 33 (26)
 3 antibiotics 13 (9) 1 (6) 12 (9)
 4 antibiotics 2 (1) 0 2 (2)
Treatment is shown in the subset of patients who received at least 1 antibiotic with poten-
tial in vitro anti–carbapenem-resistant Klebsiella pneumoniae (CRKp) activity in the first 
7 days after first positive CRKp culture. 
aOnly antibiotics with potential in vitro anti-CRKp activity were included.
Figure 4. Kaplan-Meier curve showing the 30-day in-hospital survival for patients 
with colistin-resistant carbapenem-resistant Klebsiella pneumoniae (CRKp) as compared 
to colistin-susceptible CRKp. Patients were censored at the time of hospital discharge.







Interval P  Value
Colistin resistance 3.48 1.73–6.57 < .001
Age (by decade) 1.24 1.03–1.53 .02
Origin < .01
 Home (reference) — —
 Skilled nursing facility 2.52 1.12–6.03
 Hospital transfer 2.64 1.18–6.35
 Long-term acute care 5.18 2.17–12.82
Source < .01
 Blood (reference) — —
 Urine 0.35 0.19–0.66
 Other 0.29 0.13–0.60
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at nonstudy hospitals. The intuitive link between colistin expo-
sure and ColR has been previously documented for CRKp 
and carbapenem-resistant Acinetobacter baumannii (CRAB) 
[4, 22]. Second, patients with ColR CRKp without colistin 
exposure may have received ColR CRKp from either another 
person exposed to colistin or potentially from a food source. 
The latter option would appear less likely as no such food-re-
lated transmission has been reported in the United States for 
K. pneumoniae. In contrast, person-to-person transmission of 
ColR CRKp without further colistin exposure of subsequently 
infected patients was shown to be an important mechanism of 
spread in an outbreak-related report [24]. The lack of clonality 
in ColR CRKp described in that report argues against a single 
clonal outbreak but obviously does not rule out multiple per-
son-to-person transmission events.
Previously we described various chromosomally mediated 
mechanisms of ColR for a subset of isolates in this cohort [25]. 
Of concern, 2 recently described plasmid-mediated, readily 
transmissible ColR mechanisms—mcr-1 and mcr-2—are being 
recognized in Enterobacteriaceae from animals and humans 
around the world [17, 26]. Even though mcr-1 has already been 
reported in the United States, this gene was not detected in any 
of the isolates described here [27, 28]. Reproducibility issues in 
polymyxin/colistin MIC testing, as well as variability between 
testing methods illustrated here and in other reports, may com-
plicate tracking of mcr-1– and mcr-2–carrying isolates [20]. If 
screening of mcr carriage is only performed on isolates based 
on colistin MIC by Etest, the most common method used by 
clinical labs, the spread of mcr is likely to be underestimated.
There are a number of limitations to this work. We purpose-
fully selected isolates in which colistin susceptibility testing was 
performed by the clinical microbiology laboratories as clinically 
indicated, and patients with CRKp isolates that were not tested 
are not included in this study. Therefore, our estimate of 13% 
ColR at first test may not necessarily be representative of all 
patients with CRKp. Furthermore, follow-up for patients in this 
observational study is limited to the duration of hospitalization. 
Consequently, we cannot comment on long-term outcomes. 
Another potential limitation of our work is that we included 
both patients who met standardized criteria for infection as well 
as those who did not. Nevertheless, standardized criteria have 
limitations in distinguishing patients with infection from those 
who are colonized. In addition, patients who do not meet cri-
teria for infection often receive antibiotic treatment and are an 
important source of transmission. Finally, our study population 
was predominantly derived from the Great Lakes region of the 
United States. Therefore, these data may not accurately reflect 
incidence of ColR in other CRKp in the United States. In a study 
performed by the Centers for Disease Control and Prevention 
in 2012–2013 in 7 US communities, 12 CRE isolates were tested 
for colistin susceptibility. Nine of these were reported to be non-
susceptible, based on testing performed in clinical laboratories 
[29]. Additional data from other US regions are expected from 
ongoing surveillance programs and from the recently started 
national expansion of CRACKLE. Additionally, there are 
important differences in ColR rates in CRE isolates outside of 
the United States as well [17, 26].
In summary, we observed a 13% ColR rate in this multi-
center, observational cohort of hospitalized patients with CRKp 
in US hospitals. Colistin in vitro susceptibility testing is char-
acterized by reproducibility issues. Patients with ColR CRKp 
were at higher risk for mortality. They also tended to present 
earlier during admission. This, in combination with the pol-
yclonality of the observed ColR CRKp isolates, suggests that 
direct patient-to-patient transmission of CRKp isolates within 
short-term acute care hospitals is unlikely to be the primary 
mechanism driving resistance rates. Alternative, not mutually 
exclusive explanations include within-patient development of 
ColR and transmission in healthcare settings outside of short-
term acute care hospitals, such as LTACs or SNFs.
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